A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia
| Autor: | Yinghao Sun, Keji Xie, Tie Zhou, Hanzhong Li, Margaret K. Yu, Changling Li, Vsevolod Matveev, Peter De Porre, Boris Alexeev, Zhuli Wu, Mingxing Qiu, Ye Tian, Yi-Ran Huang, Fangjian Zhou, Dingwei Ye, Hongchuan Liang, V. Naini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
030232 urology & nephrology Asian Focus Placebo lcsh:RC870-923 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Prednisone Internal medicine medicine Clinical endpoint Abiraterone Chemotherapy-naïve Performance status business.industry Abiraterone acetate medicine.disease Interim analysis lcsh:Diseases of the genitourinary system. Urology Surgery Metastatic castration-resistant prostate cancer Prostate-specific antigen chemistry 030220 oncology & carcinogenesis business Prostate specific antigen medicine.drug |
| Zdroj: | Asian Journal of Urology, Vol 4, Iss 2, Pp 75-85 (2017) Asian Journal of Urology |
| ISSN: | 2214-3882 |
| Popis: | Objective This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naive, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients from China, Malaysia, Thailand and Russia. Methods Adult chemotherapy-naive patients with confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade 0–1, ongoing androgen deprivation (serum testosterone |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|